New resistance mechanisms to azole drugs in Aspergillus fumigatus and emergence of antifungal drugs-resistant A. fumigatus atypical strains

Medical Mycology

Volumn 44, Issue SUPPL. 1, 2006, Pages 367-371

  Mellado, E ^a   Alcazar Fuoli, L ^a   Garcia Effron G ^a   Alastruey Izquierdo, A ^a   Cuenca Estrella, M ^a   Rodriguez Tudela J L ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antifungal drugs; Aspergillus; Resistance mechanisms

Indexed keywords

ANTIFUNGAL AGENT; GLYCINE; HISTIDINE; ITRACONAZOLE; LEUCINE; METHIONINE; POSACONAZOLE; PYRROLE DERIVATIVE; STEROL 14ALPHA DEMETHYLASE; VORICONAZOLE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CROSS RESISTANCE; DNA MODIFICATION; DRUG MECHANISM; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; INFECTION PREVENTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; PROMOTER REGION; SPECIES COMPARISON; SPOROGENESIS; TANDEM REPEAT;

ASPERGILLUS; ASPERGILLUS FUMIGATUS; FUNGI;

EID: 33749527045     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780600902243     Document Type: Article

References (33)

1. Singh, N. (2001) Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices Clin Infect Dis, 33, pp. 1692-1696.
2. Kontoyiannis, DP and Bodey, GP. (2002) Invasive aspergillosis in: An update Eur J Clin Microbiol Infect Dis, 21, pp. 161-172.
3. Clinical Laboratory Standard Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. M38-A. Wayne, PA. Clinical Laboratory Standard Institute2002.
4. Cuenca-Estrella, M and Rodriguez-Tudela, JL and Mellado, E and (1998) Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus J Antimicrob Chemother, 42, pp. 531-533.
5. Gomez-Lopez, A and Garcia-Effron, G and Mellado, E and (2003) In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp Antimicrob Agents Chemother, 47, pp. 3085-3088.
6. Mosquera, J and Denning, DW. (2002) Azole cross-resistance in Aspergillus fumigatus Antimicrob Agents Chemother, 46, pp. 556-557.
7. Denning, DW and Radford, SA and Oakley, KL and (1997) Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection J Antimicrob Chemother, 40, pp. 401-414.
8. Verweij, PE and Te Dorsthorst, DT and Rijs, AJ and (2002) Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998 J Clin Microbiol, 40, pp. 2648-2650.
9. Balajee, SA and Weaver, M and Imhof, A and (2004) Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals Antimicrob Agents Chemother, 48, pp. 1197-1203.
10. Balajee, SA and Gribskov, JL and Hanley, E and (2005) Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus Eukaryot Cell, 4, pp. 625-632.
11. Chandrasekar, PH. (2005) Antifungal resistance in Aspergillus Med Mycol, 43(Suppl. 1), pp. S295-2988.
12. Ghannoum, MA and Rice, LB. (1999) Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance Clin Microbiol Rev, 12, pp. 501-517.
13. Sanglard, D and Odds, FC. (2002) Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences Lancet Infect Dis, 2, pp. 73-85.
14. Pinjon, E and Moran, GP and Jackson, CJ and (2003) Molecular mechanisms of itraconazole resistance in Candida dubliniensis Antimicrob Agents Chemother, 47, pp. 2424-2437.
15. Favre, B and Didmon, M and Ryder, NS. (1999) Multiple amino acid substitutions in lanosterol 14α-demethylase contribute to azole resistance in Candida albicans Microbiology, 145, pp. 2715-2725.
16. Slaven, JW and Anderson, MJ and Sanglard, D and (2002) Fungal increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate Fungal Genet Biol, 36, pp. 199-206.
17. da Silva Ferreira, ME and Capellaro, JL and (2004) In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance Antimicrob Agents Chemother, 48, pp. 4405-4413.
18. Guerra, TM and Mellado, E and Cuenca-Estrella, M and (2003) A point mutation in the 14-alpha sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus Antimicrob Agents Chemother, 47, pp. 1120-1124.
19. Mann, PA and Parmegiani, RM and Wei, SQ and (2003) Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14-alpha demethylase Antimicrob Agents Chemother, 47, pp. 577-581.
20. Nascimento, AM and Goldman, GH and Park, S and (2003) Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole Antimicrob Agents Chemother, 47, pp. 1719-1726.
21. Mellado, E and Garcia-Effron, G and Alcazar-Fuoli, L and (2004) Substitutions at methionine 220 in the 14-alpha sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs Antimicrob Agents Chemother, 48, pp. 2747-2750.
22. Mellado, E and Diaz-Guerra, TM and Cuenca-Estrella, M and (2001) Identification of two different 14α sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species J Clin Microbiol, 39, pp. 2431-2438.
23. Mellado, E and Garcia-Effron, G and Buitrago, MJ and (2005) Targeted gene disruption of the 14-alpha sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility Antimicrob Agents Chemother, 49, pp. 2536-2538.
24. Katz, ME and Dougall, AM and Weeks, K and (2005) Multiple genetically distinct groups revealed among clinical isolates identified as atypical Aspergillus fumigatus J Clin Microbiol, 43, pp. 551-555.
25. Wang, L and Yokoyama, K and Miyaji, M and Nishimura, K. (2000) Mitochondrial cytochrome b gene analysis of Aspergillus fumigatus and related species J Clin Microbiol, 38, pp. 1352-1358.
26. Hong, SB and Cho, HS and Shin, HD and (2006) Novel Neosartorya species isolated from soil in Korea Int J Syst Evol Microbiol, 56, pp. 477-486.
27. Varga, J and Vida, Z and Toth, B and Debets, F and Horie, Y. (2000) Phylogenetic analysis of newly described Neosartorya species Antonie Van Leeuwenhoek, 77, pp. 235-239.
28. Varga, J and Rigo, K and Toth, B and (2003) Evolutionary relationships among Aspergillus species producing economically important mycotoxins Food Technol Biotechnol, 41, pp. 29-36.
29. Lonial, S and Williams, L and Carrum, G and (1997) Neosartorya fischeri: an invasive fungal pathogen in an allogeneic bone marrow transplant patient Bone Marrow Transplant, 19, pp. 753-755.
30. Jarv, H and Lehtmaa, J and Summerbell, RC and (2004) Isolation of Neosartorya pseudofischeri from blood: First hint of pulmonary Aspergillosis J Clin Microbiol, 42, pp. 925-928.
31. Padhye, AA and Godfrey, JH and Chandler, FW and (1994) Osteomyelitis caused by Neosartorya pseudofischeri J Clin Microbiol, 32, pp. 2832-2836.
32. Guarro, J and Kallas, EG and Godoy, P and (2002) Cerebral aspergillosis caused by Neosartorya hiratsukae, Brazil Emerg Infect Dis, 8, pp. 989-991.
33. Balajee, SA and Gribskov, J and Brandt, M and (2005) Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus J Clin Microbiol, 43, pp. 5996-5999.